[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Pharmaceuticals Global Group of Eight (G8) Industry Guide 2015-2024

June 2020 | 225 pages | ID: P8F9B249648EN
MarketLine

US$ 1,495.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Pharmaceuticals Global Group of Eight (G8) Industry Guide 2015-2024

SUMMARY

The G8 Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the G8 pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

KEY HIGHLIGHTS
  • The G8 countries contributed $645.3 billion in 2019 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 2.2% between 2015 and 2019. The G8 countries are expected to reach a value of $649.4 billion in 2024, with a CAGR of 0.1% over the 2019-24 period.
  • Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $409.4 billion in 2019. This was followed by Japan and Germany, with a value of $59.3 and $40.2 billion, respectively.
  • The US is expected to lead the pharmaceuticals industry in the G8 nations with a value of $417.2 billion in 2016, followed by Japan and Germany with expected values of $53.6 and $39.6 billion, respectively.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 pharmaceuticals market
  • Leading company profiles reveal details of key pharmaceuticals market players’ G8 operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the G8 pharmaceuticals market with five year forecasts
  • Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
REASONS TO BUY
  • What was the size of the G8 pharmaceuticals market by value in 2019?
  • What will be the size of the G8 pharmaceuticals market in 2024?
  • What factors are affecting the strength of competition in the G8 pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the G8 pharmaceuticals market?
1 INTRODUCTION

1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions

2 GROUP OF EIGHT (G8) PHARMACEUTICALS

2.1. Industry Outlook

3 PHARMACEUTICALS IN CANADA

3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators

4 PHARMACEUTICALS IN FRANCE

4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators

5 PHARMACEUTICALS IN GERMANY

5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators

6 PHARMACEUTICALS IN ITALY

6.1. Market Overview
6.2. Market Data
6.3. Market Segmentation
6.4. Market outlook
6.5. Five forces analysis
6.6. Macroeconomic Indicators

7 PHARMACEUTICALS IN JAPAN

7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
7.6. Macroeconomic Indicators

8 PHARMACEUTICALS IN RUSSIA

8.1. Market Overview
8.2. Market Data
8.3. Market Segmentation
8.4. Market outlook
8.5. Five forces analysis
8.6. Macroeconomic Indicators

9 PHARMACEUTICALS IN THE UNITED KINGDOM

9.1. Market Overview
9.2. Market Data
9.3. Market Segmentation
9.4. Market outlook
9.5. Five forces analysis
9.6. Macroeconomic Indicators

10 PHARMACEUTICALS IN THE UNITED STATES

10.1. Market Overview
10.2. Market Data
10.3. Market Segmentation
10.4. Market outlook
10.5. Five forces analysis
10.6. Macroeconomic Indicators

11 COMPANY PROFILES

11.1. Johnson & Johnson
11.2. Pfizer Inc.
11.3. Apotex Pharmachem Inc
11.4. Laboratoires Pierre Fabre SA
11.5. AstraZeneca AB
11.6. Novartis AG
11.7. F. Hoffmann-La Roche Ltd
11.8. Bayer AG
11.9. Boehringer Ingelheim GmbH
11.10. A Menarini Industrie Farmaceutiche Riunite Srl
11.11. Recordati S.p.A.
11.12. Chiesi Farmaceutici SpA
11.13. Daiichi Sankyo Co Ltd
11.14. Takeda Pharmaceutical Company Limited
11.15. Astellas Pharma Inc.
11.16. Mitsubishi Tanabe Pharma Corporation
11.17. Sanofi SA
11.18. Les Laboratoires Servier
11.19. GlaxoSmithKline Plc
11.20. Merck & Co., Inc.

12 APPENDIX

12.1. Methodology
12.2. About MarketLine

LIST OF TABLES

Table 1: G8 pharmaceuticals industry, revenue($bn), 2015-24
Table 2: G8 pharmaceuticals industry, revenue by country ($bn), 2015-19
Table 3: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2019-24
Table 4: Canada pharmaceuticals market value: $ billion, 2015-19
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2019
Table 6: Canada pharmaceuticals market share: % share, by value, 2019
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2019-24
Table 8: Canada size of population (million), 2015-19
Table 9: Canada gdp (constant 2005 prices, $ billion), 2015-19
Table 10: Canada gdp (current prices, $ billion), 2015-19
Table 11: Canada inflation, 2015-19
Table 12: Canada consumer price index (absolute), 2015-19
Table 13: Canada exchange rate, 2015-19
Table 14: France pharmaceuticals market value: $ billion, 2015-19
Table 15: France pharmaceuticals market geography segmentation: $ billion, 2019
Table 16: France pharmaceuticals market share: % share, by value, 2019
Table 17: France pharmaceuticals market value forecast: $ billion, 2019-24
Table 18: France size of population (million), 2015-19
Table 19: France gdp (constant 2005 prices, $ billion), 2015-19
Table 20: France gdp (current prices, $ billion), 2015-19
Table 21: France inflation, 2015-19
Table 22: France consumer price index (absolute), 2015-19
Table 23: France exchange rate, 2015-19
Table 24: Germany pharmaceuticals market value: $ billion, 2015-19
Table 25: Germany pharmaceuticals market geography segmentation: $ billion, 2019
Table 26: Germany pharmaceuticals market share: % share, by value, 2019
Table 27: Germany pharmaceuticals market value forecast: $ billion, 2019-24
Table 28: Germany size of population (million), 2015-19
Table 29: Germany gdp (constant 2005 prices, $ billion), 2015-19
Table 30: Germany gdp (current prices, $ billion), 2015-19
Table 31: Germany inflation, 2015-19
Table 32: Germany consumer price index (absolute), 2015-19
Table 33: Germany exchange rate, 2015-19
Table 34: Italy pharmaceuticals market value: $ billion, 2015-19
Table 35: Italy pharmaceuticals market geography segmentation: $ billion, 2019
Table 36: Italy pharmaceuticals market share: % share, by value, 2019
Table 37: Italy pharmaceuticals market value forecast: $ billion, 2019-24
Table 38: Italy size of population (million), 2015-19
Table 39: Italy gdp (constant 2005 prices, $ billion), 2015-19
Table 40: Italy gdp (current prices, $ billion), 2015-19
Table 41: Italy inflation, 2015-19
Table 42: Italy consumer price index (absolute), 2015-19
Table 43: Italy exchange rate, 2015-19
Table 44: Japan pharmaceuticals market value: $ billion, 2015-19
Table 45: Japan pharmaceuticals market geography segmentation: $ billion, 2019
Table 46: Japan pharmaceuticals market share: % share, by value, 2019
Table 47: Japan pharmaceuticals market value forecast: $ billion, 2019-24
Table 48: Japan size of population (million), 2015-19
Table 49: Japan gdp (constant 2005 prices, $ billion), 2015-19
Table 50: Japan gdp (current prices, $ billion), 2015-19
Table 51: Japan inflation, 2015-19
Table 52: Japan consumer price index (absolute), 2015-19
Table 53: Japan exchange rate, 2015-19
Table 54: Russia pharmaceuticals market value: $ billion, 2015-19
Table 55: Russia pharmaceuticals market geography segmentation: $ billion, 2019
Table 56: Russia pharmaceuticals market share: % share, by value, 2019
Table 57: Russia pharmaceuticals market value forecast: $ billion, 2019-24
Table 58: Russia size of population (million), 2015-19
Table 59: Russia gdp (constant 2005 prices, $ billion), 2015-19

LIST OF FIGURES

Figure 1: G8 pharmaceuticals industry, revenue($bn), 2015-24
Figure 2: G8 Pharmaceuticals industry, revenue by country (%), 2019
Figure 3: G8 pharmaceuticals industry, revenue by country ($bn), 2015-19
Figure 4: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2019-24
Figure 5: Canada pharmaceuticals market value: $ billion, 2015-19
Figure 6: Canada pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 7: Canada pharmaceuticals market share: % share, by value, 2019
Figure 8: Canada pharmaceuticals market value forecast: $ billion, 2019-24
Figure 9: Forces driving competition in the pharmaceuticals market in Canada, 2019
Figure 10: Drivers of buyer power in the pharmaceuticals market in Canada, 2019
Figure 11: Drivers of supplier power in the pharmaceuticals market in Canada, 2019
Figure 12: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2019
Figure 13: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2019
Figure 14: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2019
Figure 15: France pharmaceuticals market value: $ billion, 2015-19
Figure 16: France pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 17: France pharmaceuticals market share: % share, by value, 2019
Figure 18: France pharmaceuticals market value forecast: $ billion, 2019-24
Figure 19: Forces driving competition in the pharmaceuticals market in France, 2019
Figure 20: Drivers of buyer power in the pharmaceuticals market in France, 2019
Figure 21: Drivers of supplier power in the pharmaceuticals market in France, 2019
Figure 22: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2019
Figure 23: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2019
Figure 24: Drivers of degree of rivalry in the pharmaceuticals market in France, 2019
Figure 25: Germany pharmaceuticals market value: $ billion, 2015-19
Figure 26: Germany pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 27: Germany pharmaceuticals market share: % share, by value, 2019
Figure 28: Germany pharmaceuticals market value forecast: $ billion, 2019-24
Figure 29: Forces driving competition in the pharmaceuticals market in Germany, 2019
Figure 30: Drivers of buyer power in the pharmaceuticals market in Germany, 2019
Figure 31: Drivers of supplier power in the pharmaceuticals market in Germany, 2019
Figure 32: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2019
Figure 33: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2019
Figure 34: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2019
Figure 35: Italy pharmaceuticals market value: $ billion, 2015-19
Figure 36: Italy pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 37: Italy pharmaceuticals market share: % share, by value, 2019
Figure 38: Italy pharmaceuticals market value forecast: $ billion, 2019-24
Figure 39: Forces driving competition in the pharmaceuticals market in Italy, 2019
Figure 40: Drivers of buyer power in the pharmaceuticals market in Italy, 2019
Figure 41: Drivers of supplier power in the pharmaceuticals market in Italy, 2019
Figure 42: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2019
Figure 43: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2019
Figure 44: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2019
Figure 45: Japan pharmaceuticals market value: $ billion, 2015-19
Figure 46: Japan pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 47: Japan pharmaceuticals market share: % share, by value, 2019
Figure 48: Japan pharmaceuticals market value forecast: $ billion, 2019-24
Figure 49: Forces driving competition in the pharmaceuticals market in Japan, 2019
Figure 50: Drivers of buyer power in the pharmaceuticals market in Japan, 2019
Figure 51: Drivers of supplier power in the pharmaceuticals market in Japan, 2019
Figure 52: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2019
Figure 53: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2019
Figure 54: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2019
Figure 55: Russia pharmaceuticals market value: $ billion, 2015-19
Figure 56: Russia pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 57: Russia pharmaceuticals market share: % share, by value, 2019
Figure 58: Russia pharmaceuticals market value forecast: $ billion, 2019-24
Figure 59: Forces driving competition in the pharmaceuticals market in Russia, 2019
Figure 60: Drivers of buyer power in the pharmaceuticals market in Russia, 2019

COMPANIES MENTIONED

A Menarini Industrie Farmaceutiche Riunite Srl
Apotex Pharmachem Inc
Astellas Pharma Inc.
AstraZeneca AB
Bayer AG
Boehringer Ingelheim GmbH
Chiesi Farmaceutici SpA
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Johnson & Johnson
Laboratoires Pierre Fabre SA
Les Laboratoires Servier
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Novartis AG
Pfizer Inc.
Recordati S.p.A.
Sanofi SA
Takeda Pharmaceutical Company Limited


More Publications